Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

BridgeBio Pharma said Finance Chief Brian Stephenson is leaving the company for personal reasons and will be replaced by Thomas Trimarch, who will continue holding the president role.

In a report released on March 10, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price target of $44.00. The company’s shares closed ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Recursion Pharmaceuticals ( ($RXRX) ) has shared an update. On March 18, 2025, Recursion Pharmaceuticals announced the appointment of Dr. Namandjé ...

PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.